William Mezzanotte
Chief Tech/Sci/R&D Officer presso CSL LIMITED
Profilo
Attualmente, William Mezzanotte è Chief Medical Officer, EVP & Head-R&D presso CSL Ltd. Il dottor Mezzanotte è anche nel consiglio di amministrazione di BELLUS Health, Inc. e dell'University City Science Center. Il Dr. Mezzanotte è stato in precedenza Vice Presidente & Head-Respiratory & Inflammation presso AstraZeneca Plc e Senior Vice President & Head-Therapeutic Area presso C.H. Boehringer Sohn AG & Co. KG. William Mezzanotte ha conseguito una laurea presso la Villanova University, un dottorato presso la University of Pennsylvania e una laurea presso la Johns Hopkins University.
Posizioni attive di William Mezzanotte
| Società | Posizione | Inizio |
|---|---|---|
| CSL LIMITED | Chief Tech/Sci/R&D Officer | 01/10/2018 |
University City Science Center
 University City Science Center Investment Trusts/Mutual FundsMiscellaneous University City Science Center provides physical space, resources and other support to the community. The company was founded in 1963 and is headquartered in Philadelphia, PA. | Director/Board Member | 19/06/2020 |
Precedenti posizioni note di William Mezzanotte
| Società | Posizione | Fine |
|---|---|---|
| BELLUS HEALTH | Director/Board Member | 01/01/2023 |
C.H. Boehringer Sohn AG & Co. KG
 C.H. Boehringer Sohn AG & Co. KG Pharmaceuticals: MajorHealth Technology C.H. Boehringer Sohn AG & Co. KG operates as a holding company, with interests in the manufacturing of pharmaceutical products. It offers prescription drugs for the treatment of human respiratory, cardiovascular, gastrointestinal, and central nervous system diseases, including human immunodeficiency virus infection and cancer. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany. | Corporate Officer/Principal | 01/04/2017 |
| ASTRAZENECA PLC | Corporate Officer/Principal | 01/03/2015 |
CSL Behring LLC
 CSL Behring LLC BiotechnologyHealth Technology CSL Behring LLC researches, develops, manufactures, and markets biotherapies that are used to treat serious and rare conditions. It offers protein-based therapies in the areas of Bleeding Disorders, Fluid Replacement, Hereditary Angioedema, Immunoglobulin, Pulmonary, and Wound Healing Therapies. The company was founded in 2004 and is headquartered in King of Prussia, PA. | Chief Tech/Sci/R&D Officer | - |
Formazione di William Mezzanotte
| University of Pennsylvania | Doctorate Degree |
| The Johns Hopkins University | Graduate Degree |
| Villanova University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| CSL LIMITED | Health Technology |
| Aziende private | 4 |
|---|---|
BELLUS Health, Inc.
 BELLUS Health, Inc. Pharmaceuticals: MajorHealth Technology BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada. | Health Technology |
C.H. Boehringer Sohn AG & Co. KG
C.H. Boehringer Sohn AG & Co. KG Pharmaceuticals: MajorHealth Technology C.H. Boehringer Sohn AG & Co. KG operates as a holding company, with interests in the manufacturing of pharmaceutical products. It offers prescription drugs for the treatment of human respiratory, cardiovascular, gastrointestinal, and central nervous system diseases, including human immunodeficiency virus infection and cancer. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany. | Health Technology |
CSL Behring LLC
CSL Behring LLC BiotechnologyHealth Technology CSL Behring LLC researches, develops, manufactures, and markets biotherapies that are used to treat serious and rare conditions. It offers protein-based therapies in the areas of Bleeding Disorders, Fluid Replacement, Hereditary Angioedema, Immunoglobulin, Pulmonary, and Wound Healing Therapies. The company was founded in 2004 and is headquartered in King of Prussia, PA. | Health Technology |
University City Science Center
University City Science Center Investment Trusts/Mutual FundsMiscellaneous University City Science Center provides physical space, resources and other support to the community. The company was founded in 1963 and is headquartered in Philadelphia, PA. | Miscellaneous |
- Borsa valori
- Insiders
- William Mezzanotte
